A series of monoclonal antibodies with therapeutic potential against cancer have been
generated and developed. Ninety-one are currently used in the clinics, either alone or in …

The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …

T cell-based immunotherapies have exhibited promising outcomes in tumor control;
however, their efficacy is limited in immune-excluded tumors. Cancer-associated fibroblasts …

The digitization of health records and growing availability of tumour DNA sequencing
provide an opportunity to study the determinants of cancer outcomes with unprecedented …

The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of
the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we …

How cancer cells escape immune surveillance and resist immune checkpoint blockade
(ICB) remains to be fully elucidated. By screening candidate genes frequently gained in …

Replication stress (RS) is a characteristic state of cancer cells as they tend to exchange
precision of replication for fast proliferation and increased genomic instability. To overcome …

Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in
mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd …

Determining the balance between DNA double strand break repair (DSBR) pathways is
essential for understanding treatment response in cancer. We report a method for …